Rochester, Minn.-based Mayo Clinic has developed a framework that uses computer modeling and electronic health records to simulate “virtual clinical trials” for heart failure treatments.
Researchers analyzed data from nearly 60,000 patients with heart failure to emulate 226 completed phase 3 trials involving 17 drugs. The virtual trials accurately predicted the outcomes for all 17 drugs — seven of which had shown benefit in real-world trials — according to a Sept. 16 report.
Heart failure affects more than 6 million Americans and remains a leading cause of hospitalization and death. Mayo Clinic researchers said the framework could help prioritize repurposed drugs for clinical testing by forecasting their likelihood of success without requiring full-scale randomized trials.
The technology is part of a broader Mayo Clinic initiative led by biomedical informatician Nansu Zong, PhD, the study’s lead author. Future efforts will expand the use of AI for trial emulation, simulation and synthetic trials to improve drug development and reduce research costs.
The post Mayo Clinic tests AI to predict drug efficacy for heart failure appeared first on Becker’s Hospital Review | Healthcare News & Analysis.
Health IT
